Cardiac fibrosis is most common health problem faced by all the people with all the heart problems associated with it. Cardiac fibrosis may refer to an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts but more commonly refers to the excess deposition of extracellular matrix in the cardiac muscle. Cardiac fibrosis, which became part of normal aging process, is associated with many cardiovascular diseases, which includes heart failure, hypertension, and cardiomyopathies.
There are two forms of cardiac fibrosis noticed; they are replacement fibrosis and reactive fibrosis which is also known as perivascular fibrosis.
Several antihypertensive classes such as beta blockers and calcium channel blockers have shown its efficiency in reducing fibrosis. RAS inhibitors commonly used ACE inhibitors, Ang II receptor blockers, aldosterone antagonists are commonly used for the treatment of fibrosis in both animals nad humans.
Cardiac fibrosis is common syndrome found prevalent in U.S. Most of the pathogenicity of cardiac fibrosis is known.
The Cardiology research journals like Clinical Cardiology and Cardiovascular Medicine running by Edelweiss publications accepts all the research work, commentaries, review articles, many more articles related to Cardiac Fibrosis.